Senthil Damodaran

12PUBLICATIONS
140CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jan 12, 2026
Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer.

Akshara Singareeka Raghavendra, Senthil Damodaran, Carlos H Barcenas

|Jul 11, 2025
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors.

Blessie Elizabeth Nelson, Filip Janku, Siqing Fu

|Jan 22, 2025
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.

Mohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava

|Nov 25, 2024
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.

Funda Meric-Bernstam, Erkan Yuca, Kurt W Evans

|Oct 02, 2024
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study.

Clinton Yam, Miral Patel, Holly A Hill

|Apr 23, 2024
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.

Aditya Bardia, Ian E Krop, Takahiro Kogawa

Pageof 2

Frequent Collaborators

6 joint publications

Debu Tripathy

4 joint publications

Funda Meric-Bernstam

3 joint publications

Banu K Arun

2 joint publications

Jennifer K Litton